<SEC-DOCUMENT>0001558370-25-007410.txt : 20250512
<SEC-HEADER>0001558370-25-007410.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512163933
ACCESSION NUMBER:		0001558370-25-007410
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		25935521

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>chrs-20250512x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/12/2025 8:33:57 PM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: 23433681-3f49-4caa-8e47-a9e2414838b5 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:chrs="http://www.coherus.com/20250512" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>COHERUS BIOSCIENCES, INC._May 12, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityCentralIndexKey" id="Tc_SEzyV49KbEGaPnA3WX_I4w_2_1">0001512762</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:AmendmentFlag" id="Tc_FndKtrnypESN49tQmySFIw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="chrs-20250512.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001512762</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-12</xbrli:startDate><xbrli:endDate>2025-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.77pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_df62af79_f478_404b_b659_cd3f7cd44066"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:DocumentType" id="Narr__l5-QP3Vb0mLMlq8MjbDUg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_nwo9NELLfUWjQqfqDMZrRQ"><b style="font-weight:bold;">May 12, 2025</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:24pt;font-weight:bold;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityRegistrantName" id="Narr_LLmB-ULWM0mT45O72xB-XQ">COHERUS BIOSCIENCES, INC.</ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_4fef730f_4ab3_41d5_9b95_011d505ca620"></a><a id="Tc_i9idv3-56EmKlW7pB9OMMg_1_0"></a><a id="Tc_9DENx0CfNk28yw1xOhO4lQ_1_2"></a><a id="Tc_PDrZHTQtn0ebbwgbPZuygQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_tRR3J0d4ZUCz199omXQ_Bw_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityFileNumber" id="Tc_ISEJv57GB0uyEDmOzXNEsg_0_2"><b style="font-size:9pt;font-weight:bold;">001-36721</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityTaxIdentificationNumber" id="Tc_7Ggv7ue_dUOGepVCHHtlwg_0_4"><b style="font-size:9pt;font-weight:bold;">27-3615821</b></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.85%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br/><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br/><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><br/><b style="font-weight:bold;">Identification Number)</b></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityAddressAddressLine1" id="Narr_JOftpqNTk0qSeCWXDZqsKw"><b style="font-weight:bold;">333 Twin Dolphin Drive</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityAddressAddressLine2" id="Narr_BAn_tBi7Kkq53tm_pNa1cg"><b style="font-weight:bold;">Suite 600</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityAddressCityOrTown" id="Narr_5m7rwn71lkaLUFG3zBrtvA"><b style="font-weight:bold;">Redwood City</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityAddressStateOrProvince" id="Narr_hj6GQ-71v0efhp7aTOquVA"><b style="font-weight:bold;">CA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:EntityAddressPostalZipCode" id="Narr_YqLnWV2ec0ee1Jmu9uARXQ"><b style="font-weight:bold;">94065</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:CityAreaCode" id="Narr_6iohyN3OU0CK_W9-5sGXMQ"><b style="font-weight:bold;">650</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:LocalPhoneNumber" id="Narr_fr5en6HlsEixHOB5K8qnjg"><b style="font-weight:bold;">649-3530</b></ix:nonNumeric></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_1df92469_f3ff_4402_ae86_b7c37a7d26ea"></a><a id="Tc_R6tuS6hgYU68EeFYMrt4hQ_0_1"></a><a id="Tc_wcLfPhWZ502qgV6o9LiC_A_2_1"></a><a id="Tc_iX6HwG_PCUCCC-B9_XYMxg_4_1"></a><a id="Tc_qIa04FIxWUWPfTq3ZUNabw_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_E5JSKA47wU-n8IS0pdnUwg_0_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_tk1_Q4J74U-mafLHPu4bhg_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_yy8CLwwvG0aPPRlE5fQ1SA_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_MN0hzBxxsUmjoeZHawX3Zg_6_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_132bb9e4_a733_46a7_a748_975eae4dea5f"></a><a id="Tc_gDBB1CW680SOWkaR_QMX6w_0_0"></a><a id="Tc_53bmOHb3oEalvaPCCtXWfA_0_2"></a><a id="Tc_hzmOJGv0Z0GmfLhYXwEcrA_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b><br/><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange</b><br/><b style="font-weight:bold;">on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:Security12bTitle" id="Tc_eM3GSzBaGU2MJQWsPh1zOg_1_0"><b style="font-weight:bold;">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" name="dei:TradingSymbol" id="Tc_3VyibRF2hkuZI9nFjUojhA_1_2"><b style="font-weight:bold;">CHRS</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_h2gkvgei-UiKe61pgamRtA_1_4"><b style="font-weight:bold;">The Nasdaq Global Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_duXVhGhvqUyQl6aKC-7UAQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_71b83427_d7b3_46a9_8a49_afc58fec95a5"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:48.95pt;text-align:justify;text-indent:-48.95pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;2.02&#160;&#160;&#160;Results of Operations and Financial Conditions.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2025, Coherus BioSciences, Inc. (the &#8220;Company&#8221;) issued a press release regarding its financial results for the fiscal quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">This information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:22.3pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_78512c1d_6d75_4a0a_8741_fece6a3cdea3"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:48.95pt;text-indent:-48.95pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01&#160;&#160;&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</span>.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:7.3pt;"><td style="vertical-align:top;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:90.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style="height:6.8pt;"><td style="vertical-align:top;width:8.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="chrs-20250512xex99d1.htm"><span style="font-style:normal;font-weight:normal;">Press release dated May 12, 2025.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cover page Interactive Data file (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f8ad6cea_a36a_4fbd_b01d_517ef4a5d6be"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-indent:24.45pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Date: May 12, 2025</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">COHERUS BIOSCIENCES, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:40.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Dennis M. Lanfear</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Dennis M. Lanfear</p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>chrs-20250512xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/12/2025 08:33:56 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="chrs-20250512xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:36.78pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:147.75pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Coherus BioSciences Reports First Quarter 2025 Financial Results&#160;and Provides Business Update</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">&#8211; </i><i style="font-size:11pt;font-style:italic;">Strategic transformation to innovative oncology completed in Q2 2025 </i><i style="font-size:11pt;font-style:italic;">&#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">&#8211;</i><i style="font-size:11pt;font-style:italic;"> </i><i style="font-size:11pt;font-style:italic;">Positive</i><i style="font-size:11pt;font-style:italic;"> CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting</i><i style="font-size:11pt;font-style:italic;"> &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;"> </i><i style="font-size:11pt;font-style:italic;">&#8211; </i><i style="font-size:11pt;font-style:italic;">Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing </i><i style="font-size:11pt;font-style:italic;">&#8211;</i><i style="font-size:11pt;font-style:italic;"> </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">&#8211;</i><i style="font-size:11pt;font-style:italic;"> Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;white-space:pre-wrap;">&#8211; LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  </i><i style="font-size:11pt;font-style:italic;">&#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">&#8211; Conference call today at 5:00 p.m. Eastern Time &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">REDWOOD CITY, Calif., </b><b style="font-size:11pt;font-weight:bold;">May 12, 2025 -- Coherus BioSciences, Inc.</b><font style="font-size:11pt;"> (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2025 and provided an overview of recent business highlights.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">&#8220;The completion of the UDENYCA divestiture in April positions us to focus on our innovative oncology portfolio,&#8221; said Denny Lanfear, Coherus Chairman and Chief Executive Officer. &#8220;This includes maximizing LOQTORZI revenues, advancing our novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026, and progressing label expanding indications for LOQTORZI in novel combinations. The commercial launch of LOQTORZI continues to progress with patient demand growing more than 15% in the first quarter of 2025 versus the fourth quarter of last year.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">&#8220;At AACR last month, we reported promising early clinical data from our ongoing Phase 1 clinical trial evaluating CHS-114, which supports continued evaluation of CHS-114 in combination with other therapies, including toripalimab in HNSCC,&#8221; stated Theresa LaValle, Ph.D., Coherus Chief Scientific and Development Officer. &#8220;We believe CHS-114 has the potential to treat many solid tumors outside of head and neck cancer, including other large, underserved immuno-oncology indications, such as colorectal cancer. As an innovative, revenue-generating oncology company, Coherus is well positioned to fully realize the value of our pipeline focused on extending the survival of cancer patients.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">RECENT BUSINESS HIGHLIGHTS&#160;</b><font style="font-size:11pt;">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;background:#ffffff;">LOQTORZI&#174; RESULTS </b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">LOQTORZI is the only FDA-approved and available treatment for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), in all patient subsets and across all lines of therapy.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">LOQTORZI net product sales for Q1 2025 </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">were $7.3 million, with patient demand growing in excess of 15% compared to Q4 2024.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;background:#ffffff;">In November 2024, the National Comprehensive Cancer Network (NCCN) revised its treatment guidelines for NPC to designate LOQTORZI as the only treatment with Preferred status in NPC, both in first line (1L) with a Category 1 designation and in second line (2L) and later NPC.</font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ADVANCEMENT OF INNOVATIVE, NEXT-GENERATION </b><b style="font-size:11pt;font-weight:bold;background:#ffffff;">IMMUNO-ONCOLOGY PIPELINE</b><b style="font-size:11pt;font-weight:bold;">&#160;</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">LOQTORZI (toripalimab-tpzi)</b><font style="font-size:11pt;"> is a next-generation, differentiated PD-1 marketed in the U.S. in two indications. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Coherus plans to maximize the value of this product by:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Combining LOQTORZI with internal pipeline assets, casdozokitug and CHS-114, in additional indications; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Entering into capital-efficient external partnerships for additional label expansions. We are pursuing additional partnerships evaluating LOQTORZI with novel promising cancer agents in 2025. </font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CHS-114</b><font style="font-size:11pt;"> is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Phase 1 dose escalation is complete, establishing safety and proof of mechanism. </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company reported early clinical data at AACR 2025 from an ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic HNSCC. The data showed a confirmed partial response in a heavily pre-treated PD-1 refractory patient, a 50% depletion in CCR8+ Treg, and an increase in CD8+ T cells, consistent with anti-tumor activity, demonstrating proof of mechanism. The safety profile was consistent with advanced disease and the known safety profile of toripalimab.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company initiated a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L HNSCC in Q1 2025 with a first data readout expected in Q2 2026.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company initiated a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025 with a first data readout expected in Q2 2026.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Casdozokitug</b><font style="font-size:11pt;"> is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Enrollment is ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with the first data readout expected in 1H 2026. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The Company reported final data at ASCO-GI 2025 from a Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC. The data showed an overall response rate (ORR) increased to 38% compared to 27%</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">1 </sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">initially announced, and complete responses per RECIST v1.1 increased to 17.2% compared to 10.3%</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">2</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;previously announced and the initial assessment of 0%</font><sup style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.25pt;font-style:normal;font-weight:normal;vertical-align:top;">1</sup><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">. These data demonstrate both an increase in ORR and a deepening of responses compared to previous datasets.&#160;Importantly, responses were seen in viral and nonviral disease, and toxicity was consistent with the known safety profiles of atezolizumab and bevacizumab, with no new safety signals identified.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;background:#ffffff;">UDENYCA&#174;</b><b style="font-size:11pt;font-weight:bold;">&#160;RESULTS (DISCONTINUED OPERATIONS)</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">UDENYCA net product sales for Q1 2025 were&#160;$31.5 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In&#160;April 2025, Coherus announced the completion of the previously announced divestiture of its UDENYCA franchise for up to $558.4 million. At the closing of the transaction, Coherus received an upfront payment of $483.4 million, including $118.4 million for UDENYCA inventory, and is eligible to receive potential milestone payments of up to $75 million.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;background:#ffffff;">DISCONTINUED OPERATIONS FINANCIAL STATEMENT PRESENTATION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">In accordance with the relevant accounting rules, the biosimilar business, inclusive of the UDENYCA, YUSIMRY and CIMERLI franchises, has been classified as discontinued operations for all periods presented.&#160;The results of the discontinued </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">operations have been reported as a separate component of income on the condensed consolidated statements of operations, and the assets and liabilities of the discontinued operations have been presented separately in the condensed consolidated balance sheets.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">FIRST QUARTER 2025 FINANCIAL RESULTS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><a name="_Hlk181103325"></a><b style="font-size:11pt;font-weight:bold;">Net revenue</b><font style="font-size:11pt;"> from continuing operations was $7.6 million and $2.3 million for the three months ended March 31, 2025 and 2024, respectively. The increase of $5.3 million was primarily due to higher volume of LOQTORZI, which launched in December 2023. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 36pt 0pt 0pt;"><font style="font-size:11pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Cost of goods sold (COGS) </b><font style="font-size:11pt;">from continuing operations was $2.7 million and $1.4 million during the three months ended March 31, 2025 and 2024, respectively. The increase was primarily due to higher volume of LOQTORZI, which launched in December 2023. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Research and development (R&amp;D) </b><font style="font-size:11pt;">expenses from continuing operations were $24.4 million and $28.4 million for the three months ended March 31, 2025 and 2024, respectively. The decrease was primarily due to the reduction in co-development costs for toripalimab, termination of the TIGIT Program announced in January 2024 and savings in personnel and stock-based compensation from reduced headcount, partially offset by increased costs for development of casdozokitug and CHS-114. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Selling, general and administrative (SG&amp;A)</b><font style="font-size:11pt;"> expenses from continuing operations were $26.0 million and $40.2 million during the three months ended March 31, 2025 and 2024, respectively. The decrease was driven primarily by the net $6.8 million charge in the first quarter of 2024 associated with the full write-off of the out-license intangible asset and associated release of the contingent value right liability related to NZV930, which was acquired in the Surface Oncology, Inc. acquisition, as well as lower average headcount and decreased operating costs following Coherus&#8217; recent divestitures. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Interest expense </b><font style="font-size:11pt;">from continuing operations was $2.2 million and $3.1 million during the three months ended March 31, 2025 and 2024, respectively. The decrease was primarily due to prepaying the remaining $75.0 million of the principal amount due under the 2027 Term Loans on May 8, 2024, partially offset by interest on the $38.7 million senior secured term loan facility and the LOQTORZI portion of the Revenue Participation Right Purchase and Sale Agreement among Coherus and Coduet Royalty Holdings, LLC (Revenue Purchase and Sale Agreement), which each commenced May 8, 2024.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Net loss from continuing operations </b><font style="font-size:11pt;">for the first quarter of 2025 was $47.4 million, or $(0.41) per share on a diluted basis, compared to $68.0 million, or $(0.60) per share on a diluted basis, for the same period in 2024. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Non-GAAP net loss from continuing operations</b><font style="font-size:11pt;"> for the first quarter of 2025 was $40.9 million, or $(0.35) per share on a diluted basis, compared to $53.6 million, or $(0.48) per share for the same period in 2024. See &#8220;Non-GAAP Financial Measures&#8221; below for a discussion on how Coherus calculates non-GAAP net loss from continuing operations and a reconciliation to the most directly comparable GAAP measures.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Net income (loss) from discontinued operations, net of tax</b><font style="font-size:11pt;"> was a net loss of $9.2 million, or $(0.08) per share on a diluted basis, for first quarter of 2025 compared to net income of $170.9 million, or $1.52 per share on a diluted basis, for the same period in 2024. The change was primarily due to the $153.6 million gain on sale of the CIMERLI ophthalmology franchise in March 2024 and the negative impacts on UDENYCA revenues in Q1 2025 following the temporary supply interruption experienced that occurred in Q4 2024, including supply allocations to wholesalers which were not removed until the end February 2025.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 0pt;"><font style="font-size:11pt;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Cash and cash equivalents </b><font style="font-size:11pt;">totaled $82.4 million as of March 31, 2025, compared to $126.0 million as of December 31, 2024. The upfront, all-cash consideration of $483.4 million</font><font style="font-size:11pt;"> for the </font><font style="font-size:11pt;">divestiture of the UDENYCA&#174; franchise was received in April 2025 and thus will be reflected as part of Coherus&#8217; Q2 2025 financial information, when reported. Also to be reflected as part of the Q2 2025 financial information, will be the use of a portion of the divestiture proceeds in April 2025 to pay $47.7 </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">million to buy out the portion of the Revenue Payments rights with respect to UDENYCA in accordance with the Revenue Purchase and Sale Agreement, and the April 2025 payments to repurchase approximately $170 million aggregate principal amount of Coherus&#8217; 1.5% Convertible Senior Subordinated notes due 2026 (2026 Convertible Notes). Coherus further expects to repurchase the remaining approximately $60 million aggregate principal amount of 2026 Convertible Notes on May 15, 2025 pursuant to the Fundamental Change Repurchase Right (as defined in the indenture, dated as of April 17, 2020, between Coherus and U.S. Bank Trust Company, National Association).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Conference Call Information</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;background:#ffffff;">When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call</font><font style="font-size:11pt;">:</font><font style="font-size:11pt;background:#ffffff;"> https://register-conf.media-server.com/register/BI10abfcf9d1e54d7da1d123eb9ffd9be0 </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Please dial in 15 minutes early to ensure a timely connection to the call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Webcast: </font><font style="font-size:11pt;">https://edge.media-server.com/mmc/p/rj9hzxof</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;"> </font><font style="font-size:11pt;background:#ffffff;">An archived webcast will be available on the &#8220;Investors&#8221; section of the Coherus website at </font><font style="font-size:11pt;background:#ffffff;">https://investors.coherus.com/events-presentations</font><font style="font-size:11pt;background:#ffffff;">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">About Coherus BioSciences</b><font style="font-size:11pt;">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Coherus is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI&#174; (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head &amp; neck, and other cancers. Our strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners&#8217;, driving sales multiples and synergies from proprietary combinations.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Coherus&#8217; immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors including in NSCLC and in HCC. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1 studies in patients with advanced solid tumors, including HNSCC and gastric cancer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit </font><font style="font-size:11pt;">www.loqtorzi.com</font><font style="font-size:11pt;">. </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Forward-Looking Statements </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus&#8217; expectations about identifying sales multiples and synergies; the ability of Coherus&#8217; I-O pipeline to enhance outcomes for cancer patients; Coherus&#8217; expectations about repurchasing the remainder of the 2026 Convertible Notes; Coherus&#8217; ability to receive either of the potential milestone payments related to the divestiture of its UDENYCA franchise; expectations for the timing of data readouts for Coherus&#8217; product candidates; Coherus&#8217; ability to enter into additional partnerships; and Coherus&#8217; ability to grow LOQTORZI revenues.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus&#8217; actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks related to Coherus&#8217; existing and potential collaboration partners; risks of Coherus&#8217; competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review and the timing of Coherus&#8217; regulatory filings; the risk of FDA review issues; the risk that Coherus is unable to complete commercial transactions; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus&#8217; business in general, see Coherus&#8217; quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the Securities and Exchange Commission on or about the date of this press release, including the section therein captioned &#8220;Risk Factors&#8221; and in other documents Coherus files with the Securities and Exchange Commission. Coherus&#8217; results for the fiscal quarter ended March 31, 2025 are not necessarily indicative of its operating results for any future periods.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;background:#ffffff;">LOQTORZI</font><font style="font-size:11pt;">&#174;, whether or not appearing in large print or with the trademark symbol, is a registered trademark of Coherus BioSciences, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#169;2025 Coherus BioSciences, Inc. All rights reserved.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">References</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">1</sup><font style="font-size:11pt;">&#160;Coherus to Acquire Surface Oncology (2023,&#160;June 16) [</font><font style="color:#0000ff;font-size:11pt;">Press Release</font><font style="font-size:11pt;">]</font><font style="font-size:11pt;"><br></font><sup style="font-size:8.25pt;vertical-align:top;">2 </sup><font style="font-size:11pt;">Daneng Li&#160;et al.,&#160;</font><i style="font-size:11pt;font-style:italic;">JCO</i><font style="font-size:11pt;">&#160;42, 470-470(2024).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Coherus Contact Information:</b><font style="font-size:11pt;"><br></font><font style="font-size:11pt;">For Investors:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Jodi Sievers</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">VP, Investor Relations &amp; Corporate Communications</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;background:#ffffff;">IR@coherus.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">For Media:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Argot Partners</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">(212) 600-1902</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">coherus@argotpartners.com</font><font style="font-size:11pt;"> </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration-line:none;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 36pt 0pt 36pt;"> <font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Coherus BioSciences, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands, except share and per share data)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(unaudited)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,599</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,308</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,653</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,439</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 24,356</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 28,424</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 26,025</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 40,232</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><font style="white-space:pre-wrap;">   Total costs and expenses</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 53,034</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 70,095</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (45,435)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (67,787)</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,150)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,118)</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 187</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,869</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss from continuing operations before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (47,398)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (68,036)</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (47,398)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (68,036)</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net income (loss) from discontinued operations, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (9,171)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 170,911</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net income (loss) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (56,569)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 102,875</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net loss from continuing operations - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.41)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.60)</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net income (loss) from discontinued operations - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.08)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1.52</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net income (loss) per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.49)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 0.91</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Weighted-average number of shares used in computing net income (loss) per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 115,857,780</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 112,749,306</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Coherus BioSciences, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(unaudited)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#0a0a0a;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 82,411</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 125,987</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Trade receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 60,488</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 111,324</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">TSA receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,948</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,010</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,518</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,207</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 52,979</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 53,646</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 30,750</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 25,936</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 138,972</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 116,423</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 371,066</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 448,533</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Accrued rebates, fees and reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 147,738</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 164,867</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">TSA payables and other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 128</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,026</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Term loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 36,781</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 36,698</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 228,569</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 228,229</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 141,320</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 139,703</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Total stockholders&#39; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (183,470)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (131,990)</font></p></td></tr><tr><td style="vertical-align:middle;width:70.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Total liabilities and stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 371,066</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 448,533</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Coherus BioSciences, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(unaudited)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 126,250</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 103,343</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (25,826)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (46,766)</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Proceeds from maturities of investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,200</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Proceeds from sale of investments in marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 8,688</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Cash received (paid) related to the Sale Transactions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (4,719)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 187,823</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Milestone payment to Junshi Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (12,500)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Other investing activities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (267)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 52</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (17,486)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 202,763</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1,507</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Taxes paid related to net share settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (264)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (745)</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Other financing activities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 125</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (264)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 887</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (43,576)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 156,884</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 82,674</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 260,227</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Reconciliation of cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">  Cash and cash equivalents</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 82,411</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 259,775</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">  Restricted cash balance</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 263</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 452</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 82,674</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 260,227</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:always;width:89.41%;border-width:0;"><div style="max-width:100%;padding-left:5.29%;padding-right:5.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-GAAP Financial Measures</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To supplement the financial results presented in accordance with GAAP, Coherus has also included in this press release non-GAAP net loss from continuing operations, and the related per share measures, which exclude from net loss from continuing operations, and the related per share measures, stock-based compensation expense, amortization of intangible assets, impairments of intangible assets and change in fair value of our Royalty Fee Derivative Liability. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus&#8217; business. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Coherus&#8217; results from period to period, and to identify operating trends in Coherus&#8217; business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">Coherus BioSciences, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11.5pt;font-weight:bold;">Reconciliation of GAAP Net Loss from Continuing Operations to Non-GAAP Net Loss from Continuing Operations</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands, except share and per share data)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(unaudited)</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.83%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">GAAP net loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#00b050;font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (47,398)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (68,036)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Adjustments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><font style="white-space:pre-wrap;">     Stock-based compensation expense</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,046</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,816</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><font style="white-space:pre-wrap;">     Impairment of out-license asset and remeasurement of CVR liability, net</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 6,772</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><font style="white-space:pre-wrap;">     Change in fair value of Royalty Fee Derivative Liability</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 810</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><font style="white-space:pre-wrap;">     Amortization of intangible assets</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 667</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 863</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Non-GAAP net loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (40,875)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (53,585)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">GAAP</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net loss per share from continuing operations, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.41)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.60)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Shares used in computing basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 115,857,780</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 112,749,306</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Non-GAAP</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net loss per share from continuing operations, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.35)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.48)</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Shares used in computing basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 115,857,780</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 112,749,306</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.29%;margin-right:5.29%;margin-top:30pt;page-break-after:avoid;width:89.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>chrs-20250512xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chrs-20250512xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( 2$# 2(  A$! Q$!_\0
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MRZF4?-+(ZAN3W !P/85Y1^U=\*Y9/"NAZQH\#/;Z);BSFB09*0#&QOHO(/\
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MV#)/_1T5?9-<7%-6<L=[-OW4E9>IZ7 .'I0RGVT8^]*3N^KMLO3R/AGX@_\
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>chrs-20250512.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 8:34:04 PM-->
<!--Modified on: 5/12/2025 8:34:04 PM-->
<xsd:schema targetNamespace="http://www.coherus.com/20250512" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:chrs="http://www.coherus.com/20250512" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20250512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20250512_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="chrs-20250512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>chrs-20250512_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 8:34:04 PM-->
<!--Modified on: 5/12/2025 8:34:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="chrs-20250512.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.coherus.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>chrs-20250512_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 8:34:04 PM-->
<!--Modified on: 5/12/2025 8:34:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>chrs-20250512_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/12/2025 8:34:04 PM-->
<!--Modified on: 5/12/2025 8:34:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="chrs-20250512.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.coherus.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638826788441849102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638826788441849102" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638826788441849102" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638826788441849102" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638826788441849102" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638826788441849102" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638826788441849102" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638826788441849102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638826788441849102" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638826788441859137" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638826788441859137" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_638826788441859137" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_638826788441859137" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638826788441859137" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638826788441859137" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638826788441859137" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638826788441859137" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638826788441859137" order="17" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638826788441859137" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638826788441859137" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638826788441859137" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638826788441859137" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638826788441859137" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638826788441859137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638826788441859137" order="23" use="optional" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COHERUS BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3615821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Twin Dolphin Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-3530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CHRS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001512762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /"$K%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( /"$K%J(>1,>[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%JPS ,AE]E^)XH<>A@)O6EHZ<.!BML[&9L
MM36+'6-K)'W[)5Z;,K8'V-'2[T^?0*T.0O<1GV,?,)+%=#>ZSB>APYJ=B((
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M:IU*)>0Q$RF7@BBV&5M3Y_;.[9L!>8\_.-NG)V5BIK*6\HNIS,.Q91LB%K%
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M-")_\H1X,FR,9(OB3<\>8(OLG.0'!S>FG P2_GD47&#01X-4)P(']?')1QE
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ \(2L6I>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /"$K%J!P"-/@P0  &@1   8
M          " @2$(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #PA*Q:GZ ;\+$"  #B#   #0              @ ':#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( /"$K%J7BKL<P    !,"   +
M  "  ;8/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /"$K%H<.&7J/P$  #P"
M   /              "  9\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #PA*Q:)!Z;HJT   #X 0  &@              @ $+$@  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #PA*Q:99!YDAD!  #/ P
M$P              @ 'P$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
."0 ) #X"   Z%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="chrs-20250512x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.coherus.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>chrs-20250512.xsd</File>
    <File>chrs-20250512_def.xml</File>
    <File>chrs-20250512_lab.xml</File>
    <File>chrs-20250512_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="chrs-20250512x8k.htm">chrs-20250512x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "chrs-20250512x8k.htm": {
   "nsprefix": "chrs",
   "nsuri": "http://www.coherus.com/20250512",
   "dts": {
    "schema": {
     "local": [
      "chrs-20250512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "chrs-20250512_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "chrs-20250512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "chrs-20250512_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "chrs-20250512x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.coherus.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20250512x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "chrs-20250512x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.coherus.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-25-007410-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-007410-xbrl.zip
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MN,SM4MI\N>I6\9E>XB5[/>.#^)H#/.KF*94Y*YD_!KY$24>-F@,W:9VXIW\
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M1YYGV38X\2R]B^)'.#:'_\-_ ,/$8YU 'S_J.N6D2[JQ$H],FJ4\Q^=YEI=
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M/%O0:@G?6%U\Z%1^<K+L]NYOE).APE+FF^-1R/,=BE,LW$/HH1=-O'R@OT+
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M>AWKNH=\/_[GRG(0EXJG?&L:0?^I<?O(/K51Y>[^].')OQR^P16"((#;H>6
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M%Z+,G+722G.<._+Z>0[> <$\[$5$3#--NG/".0>3+?U#;% "/U1_X!='M$+
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M=C49P4K;K1^5Q2<,-,6K\ +.GL"-,6XV7@"+!\_4KO!!!9 I[&%5;F_.:+V
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MH6JM1&H>&F .XCE@(01KW-"+A#7WSR9.IEE4EJH9EBH$2UT&Y KTRG@@<G@
M*J+:N:(JW @4&;$1"V)TTUP(4'#%DH<P^@:ZXN+BZA2ABX=XP@,%,=-'=RF
M*Z$@D#=!K2!5NRR&105 ./-P4$W3S6[G?/,U8D,6(4.@VDJY(P8>9!',_<,_
MA%N#HYH3^].IN(O".!-V%T93P,;JA2JZ 3?%#."O*^^JPUWXN4_1[0$/7\%P
M"^F-<XF(.O4WM*0WI.2=9"'.QP.4H:O^@W?:W"X5HQ8_1U$F!#)BJ'!\VO]+
MC?_O3)O3_!<R%1!><\83!.7?M653EQ]I>9[R$SW-\W$"Z83>L<H *.!;A0YA
M9GWJ/]!I+->QVZLV;2439,YG[5%B:$G339^ -AS>=)]%9/I>U/*%T#:$S.?O
M?S^_NOCP&7'SEX_D\NKJR^_GMY>_?[#(U8?_<UOYY</5AVOXX,O5AB&6Y9+Q
M\^??KKY4OEQ=?/GTY9=_DZ^77S]\ JR^:?1&@_,&HR\EY/8+(+IF#)YH[L=*
M,OG3.UTC#@;XBH(9"4-3'C>TUEQOR".CB<=]EE_?5VP"@_VF\@9Y$*5Z4^6_
M/X2ZOZ^Z=]?8X[5;.6'E.ISX\#;4Q#*H\LA1F&#@15G6@VE?GU.N[4T#X7)G
M;R+180QA+F['+30/#1<T+S.?-(W1OV#-91^)2*&*8*!'8I8&IS'>&5YG4)*A
MVFU1[0>D3H'/04XZ=(()-!6&X2>.XC%H(JB71@GHCGCD303(T0A4BPS'0CW\
M"Z@\8F221G&*3]<NGGN0%KZ;YQH10)[%"%6.YQW/+A8QZI:FAA9887GQ5GNB
MU6[E7.=+:;"N?N<I)5, ?)BWA@#6F2:A/T4'Z%PJ-X;+X5D3YF#DD?M-06ZY
ML8SW,V43X!<NXV4$,7_"_Q;!1(# =RD@ (2<MT*@D)-;^# ^55L'RG5823""
MF/!GPP96LP"NR!^/X<T"J'IQ5JY@P>>X?1X0!^QY3(<LF:H\!(SL#<F8.2,:
M>/%XW@3)M> SZCJ'@N]VE@\VRTE8EHE 91X#][;RM 3,[=H\*X'.6-/2>'.Q
MUL)"+]$X#$(9:%"NG(4DA4>9"/.U%UEXY*T6">')"B(3A\\M'H4/&&;!'(FA
M%XTQ+0/$LTQ]FX HYSE3%),&[F$[4#Y4$EE_RP$#R(N(.EP8R/?C3%NU'Z7L
MD#FQ0GZ@E!!Y13PA ,M_Q0LNWN.W@DDM'$SLQ4GF&>-+)&0/Q?4#+&>A>QDN
M2V3ZP#+Y@+.4(@2^'GJ^R %>>+H*&KE>S,>#XT.<\ TH.WC\!(0-LV4OJL/:
M2*2<2R20)A*6TUGUBQ0E>J'"G%#@FC6<) AUQ2>B.$M4RXBZ&"T_7?J/GREG
M$-6#[:)2N@$=QT?IC^K"=D#R.?!K+@"&<C@Z+S2?R+K(AV]G!3C<\6F,]H,T
MQH 2 2^2RT^5>@>-"'H7@F60R#CUS(" 79\SMZ2-P?V>*D97T0P=$*2?+KB9
MP*,E7+X!(2&XY;]J"2:.<WUQ(8)N.OWJKQ@Q,)Q"O!%05:3?_"O<6C4HQTC:
MU[AWLK)(+]YY9>0L^?ZYZLA5GIM<4[FQ)W)(Y4NQ/%9Q:1#^YN)+Y9=+'<5G
M]+^<Z$$O_!GZ@M*74_T2("VJOJBOX6=4,.3DR_7U:09Y><Y3HSN? U7O_*AX
M(DY?KZ6[U7IKW15\3!HA%M/:P*(PD -LIS )>4)G$(0I@G-+J5#N)\P6-R83
M,/"N/UQ<WMR2>[MJSR^QW:G6YQ?9KE4;^5KF^J%6683J)YC0%*:QOMB9!T1N
M! ]8Q;$HKA^26KX6T#[4 G+VCZ4 T*Q)D;#UR,,%_"\<7W EFS >)^1UH8J0
M=2I5F\(?C;'"JMBLRS'*-K!D_:FEW<HS,6/&N*?MWHMPQ["^)PS$']*Q)7@H
M";][#IJ>RWQA3[F]>-*F+A#YHS2A:&6N_P 4DKR9)Z/Y,?%<4>;$W!60*B?Q
MFF-$74LS@F3YK"@ >5D:D*H:.7E_"=KWZO;RZK</[\F7KS)OZ>:T&.4DF&QH
M;+Z\V7QZYXZGL^-1- IBG&O38;R9AA*W1HF7@: PT5D R6Y6O#JSJ9*E30J6
MFE]ZQP*X#E/-%;4/ :L[(]#GG,K!_ )KX8=6JUMM9J1-SA/Q,C^,I96!?_+&
M@>AWPM0_-3QL2^&)0BMX&, B6+H)G2I+[X=FMS%[LEXD_(-M:^_D@U%#]()[
MN#V,IL+>\&+"8,L]7L 5JC=J5<M9ZP'U9FYLR*EUUF'9Y:8#%]L%LQV6:N(B
MY"LO'?@3:I]\O+PZO[JX//]$;F[/;T6*\U<P%N!??H5)'WY9XX5+="P[(-XQ
M[C$SZ"/F@Z$.]^&7:<#CY5'J8U<#_'K@@9R \=(H:T\C.9V7P<QW4['(OW^[
MN?Q\_6^1KWCY^</UI\N95(([L2W! +$(=\9SJQ_S&9YHH24RR;#X$M8C=.-9
M=T@)>6[Y!$07'CF4N4?IFU"TDI6Z*5DI:<G*LZRJ<<"(WC/!,9GKDL8\6VA"
MN3L!K090CT(E V.&8RP@DP9% "()O5V(Y+'A!X]F\2XDF2K5&]8ISXY(01;%
M8![E LYCRSELZ5!G35S5,/VI"BL\,:@!];E<BD>,Y:_M59Z!_88AU(^7US>W
MY)^_G5_??I!I:S.-*S%YGE1LWI>>DH".X37__U?_F]VU[5JC46^A84DWVI:K
M68O)-0+;/$0AF9!;\3,NE(TLVW.-+'^H:YTM5;NZ9!0Q)GHOQ4_WK!.5L.A.
M%-F)_E0$-C+W)2*!EO9X' !@'5@E3 ET4V[88_HQB\A]Z*=CIG?U4OV81+\O
M$05\#RA 5>$V#E!,U&C/*>(U*@J%0BIV2>%%&',=<A>BI062V24G%U]^N3DE
MSQ/D<_18KW;FZ='6X*&;1JKMTI9(LO D6'"9N$GO)[ 4^ [CQKI:C[.3Z[_2
M\>3L_3KDARD$/-:QB@YY0XIZ4R,\(1D?>RI>3X<N6T6' G2A1U)F/SMA19^X
M WPH>XK.$BL C+%HK!*$I"%V>_G+Y2T>)W(7T;'F(8)G_H,&*8VF?(A\K#&]
MAP7AM3&P)G$8!$S$@>(D=+Y5!E189&-<2/$2OI9\H/ -MH7C\-!2*> PH7 X
MC+&&8ZK%56>CU^?T*'JNE[,9YMH=<]TP(.O@SB*BL%=L.'6!CCR1&P\&^\G-
M+YS1SM<I%=Z T=K5VCRC-6O5^O9E_ARON1%\$V@L-YCR5V 4X(=VM9N]'@_Z
MNF.K.H(V$02%CC<[@8Q?F?H^>8C0*0W$K_@P3).*[SE,U$,D-!#^3(ZBQ)+/
M'H7N%FDU232$'A?D$5%XS"V)#'5APHK/[P/!<?7?O_<:-:6M<+[4^2/UHED]
M]DT:#2F J"^R7:)HA2PN$UB75X_PAHGPKQ\^8-$<IJ3 8F0L+D6QXFBYM5AE
M)WG;]T73'NDGYCVQ.V>JB['FGSY )?CQ,/<E^H]@I153;L5,J\_S;*-J[YAE
M%]3C)&(3.E5OBMB8BK+I'SHM3:)D 1+0/*@C"1USTL6'\*ZD_&L808?<@N(D
MGT*L]8<;L8%XUY)C6Z[*Y+)*)\H/C:YFO,8L\$"WQ5@^A5R)S_;AV03X3C"L
M\J%D!:OHM=&&?"T/'/B*[\:Q\R^O.=M_36$159'1#049<GX'*\U5*$QPQG)"
M@88PVX1<AU/JPXM_!;) %6^13Y\NP'Q2[WGZF:=*EC */WCS96X_:&MD'#$[
MXU]$_#ZV#US!E6NPM+18EW>UYES=[.A1.KC^AY-:M6F?\NRX>(25V,CO(+C]
M5+CB8H_7V<U2CGYH=V?,ESVC77ON&6IT,07()9SXLCK;V'V[)*TPJ/QR?OZ5
M&S[/T-@ZWJ8U:*Q6[2W01Z.U$8VU&C.OU8Q.N_HS5M+3#6.J(7:V +-C&#^#
MRD&31'5O'@ X>1 !)N[13F-^8!G\_P@^5W+6H;Z#Y>Q@\@8;+*I,YHNPO1KJ
MA>PX/AS\&!TMKH=]L'W9T3KB:27\Z6,Y3B-Y=RIY9:3D!#?R5.SDD^?XX(:C
M]J;?UV 6;I?/: 2]H[V96971=:V[CNQ<SG$ZUP2SN>"K[,X"(]K55OTU8IH?
MS# "4+/"G_&#K3,ON0.;#5^$&5?*[E'1X' R2D;4'XM^[K.,%2^0-F3FLA#(
M[4[ 5 ^F["3<A%.I).K<"[V$;P9.N)W*,"46_2#8[M^7QEV43C@[HMT<>4SF
MWU#88X<7Q8LJOZ:T$6=9+?(98"^&ZF +F/[#*/093C2*%3)# !R$Z,\?\S[%
M&%7W^8# 5B8?V2!2OIG6+KC\99[L!3[)GVN;?^1A^##IST]T\S)"X7!T\!<&
MZ!C -P^(/L_@29C M8"-NG7=E<@Y?1X$/5)O]KQ+A-^0N9GE/9+=9+*5A;16
MX6/DJ=BN%$F+R5=/MOE=JL?7NOI1FIF6Y2&[OL]8%\5"EBN6':*3X<!DE&+7
M"=\'G:N=G(:R!.0:/VMCWI&@CJ2=G;3D!=FAMHA9M&AXE9S[<8@+_-3#<>3/
M/5$.#B]-A7.&/L9M^GI,HM!AS(T?31;1*T G-+@[A4X]:9C4DY*FGBP<!+%2
M!BAAA=R53M'/*<^4><*C(1,T^1IEC6:X^P<?,4L!79J(MH;#8I:AHG%=EA?*
M\T<GV=UX2L!WL%5X\@D:1C/9>P</O,/DF07_T:(P O/I1SPFD*<HHY5^(UQ
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M>>[-SLZ,QM,9QIXK1YWUHM4.@A;-F(4U=H_GO?HI9HWQLV!Y<A@_#5:@;W$
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M-3$R7V1E9BYX;6Q02P$"% ,4    " #PA*Q:TDS.58,%   D/@  %0
M        @ &/!P  8VAR<RTR,#(U,#4Q,E]L86(N>&UL4$L! A0#%     @
M\(2L6I3V'E?-!   \"D  !4              ( !10T  &-H<G,M,C R-3 U
M,3)?<')E+GAM;%!+ 0(4 Q0    ( /"$K%KRZ?C"(!4  ->;   4
M      "  442  !C:')S+3(P,C4P-3$R>#AK+FAT;5!+ 0(4 Q0    ( /"$
MK%JR<D>$.CL  .U9 P 8              "  9<G  !C:')S+3(P,C4P-3$R
A>&5X.3ED,2YH=&U02P4&      8 !@"0 0  !V,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>chrs-20250512x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="chrs-20250512.xsd" xlink:type="simple"/>
    <context id="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001512762</identifier>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_SEzyV49KbEGaPnA3WX_I4w_2_1">0001512762</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_FndKtrnypESN49tQmySFIw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr__l5-QP3Vb0mLMlq8MjbDUg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_nwo9NELLfUWjQqfqDMZrRQ">2025-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_LLmB-ULWM0mT45O72xB-XQ">COHERUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_tRR3J0d4ZUCz199omXQ_Bw_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_ISEJv57GB0uyEDmOzXNEsg_0_2">001-36721</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_7Ggv7ue_dUOGepVCHHtlwg_0_4">27-3615821</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_JOftpqNTk0qSeCWXDZqsKw">333 Twin Dolphin Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_BAn_tBi7Kkq53tm_pNa1cg">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_5m7rwn71lkaLUFG3zBrtvA">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_hj6GQ-71v0efhp7aTOquVA">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_YqLnWV2ec0ee1Jmu9uARXQ">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_6iohyN3OU0CK_W9-5sGXMQ">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_fr5en6HlsEixHOB5K8qnjg">649-3530</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_E5JSKA47wU-n8IS0pdnUwg_0_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_tk1_Q4J74U-mafLHPu4bhg_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_yy8CLwwvG0aPPRlE5fQ1SA_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_MN0hzBxxsUmjoeZHawX3Zg_6_0">false</dei:PreCommencementTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_eM3GSzBaGU2MJQWsPh1zOg_1_0">Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_3VyibRF2hkuZI9nFjUojhA_1_2">CHRS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Tc_h2gkvgei-UiKe61pgamRtA_1_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_12_2025_To_5_12_2025_RnxJ5iuGeUKEDLioqW9SWw"
      id="Narr_duXVhGhvqUyQl6aKC-7UAQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
